The OTEZLA® international website
This site is intended for healthcare professionals outside the U.S.
The OTEZLA® international website
This site is intended for healthcare professionals outside the U.S.
About psoriatic arthritis1
Psoriatic arthritis is a systemic imunomediated disorder characterized by inflammation of joints, surrounding ligaments and tendons, and psoriatic skin lesions.1
Psoriatic arthritis has a significant negative impact on patient functionality, psychology, and quality of life. In one study, psoriatic arthritis was significantly associated with reduced work productivity.2-5
Many patients are diagnosed with psoriatic arthritis approximately 10 years after initial skin symptoms develop.6
Where can I find more information and support?
On November 21, 2019, Amgen acquired from Celgene Corporation the worldwide rights to Otezla® (apremilast).
Effective November 21, 2019, refer to the Amgen's Terms of Use relating to the access of Amgen websites, applications and digital services and Privacy Statement concerning the collection and use of your personal information.
For information collected by Celgene prior to November 21, 2019, refer to Celgene's Terms of Use and Privacy Policy.